Results 71 to 80 of about 2,052,688 (283)

Structural Basis of Shiga Toxin Neutralization by Human Antibodies Targeting Canonical Receptor‐Binding and Non‐Canonical Assembly Sites

Advanced Science, EarlyView.
Cryo‐electron microscopy structures reveal two distinct neutralization mechanisms of fully human monoclonal antibodies targeting the Shiga toxin 1a B subunit. RDS059 occludes the Gb3 receptor‐binding site, whereas RDS045 engages a lateral quaternary epitope to disrupt holotoxin assembly.
Jianting Ke, Xin Li, Xiaoli Wang, Zhaoxia Huang, Shaojie Xue, Yuyang Liu, Jing Pan, Guowei Hu, Yayu Wang, Cheng Wang, Shoudeng Chen   +10 more
wiley   +1 more source

Multi‐Technique Integration Identifies O‐GlcNAc Transferase in Fibroblast‐Like Synoviocytes as a Therapeutic Target for Rheumatoid Arthritis

Advanced Science, EarlyView.
AI‑guided single‑cell transcriptomics identifies OGT as a key regulator enriched in rheumatoid arthritis fibroblast‑like synoviocytes (RA‐FLSs). Inflammatory stimuli activate the OGT–SAP130 axis, which modulates the H3K27ac/H3K27me3 balance and epigenetically silences BTG2, promoting aggressive transformation of RA‑FLSs.
Duoli Xie, Jie Huang, Chunhao Cao, Zhenchao Tang, Xingchen Li, Jianmin Guo, Xinxin Chen, Fang Wang, Dongyi He, Jie Li, Yu Du, Bing He, Jianhua Yao, Aiping Lu, Chao Liang   +14 more
wiley   +1 more source

Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013–2025

Human Vaccines & Immunotherapeutics
CAR-T cell therapy has dramatically changed the treatment paradigm for relapsed/refractory multiple myeloma (R/R MM). Nevertheless, there is a notable paucity of comprehensive bibliometric analyses within this specialized domain.
Tiantian Zhang, Shenyu Wang, Xin Li, Xiaohong Li, Yamei Wu   +4 more
doaj   +1 more source

Engineering better chimeric antigen receptor T cells

Experimental Hematology & Oncology, 2020
CD19-targeted CAR T cells therapy has shown remarkable efficacy in treatment of B cell malignancies. However, relapse of primary disease remains a major obstacle after CAR T cells therapy, and the majority of relapses present a tumor phenotype with ...
Hao Zhang, Pu Zhao, He Huang
doaj   +1 more source

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

Advanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang, Dan‐yun Ruan, Jing Shi, Yue Huang, Hui Sheng, Ya‐ling Huang, Linjie Ma, Lijun Wang, Caiwei Chen, Yixuan Wang, Yue Zhang, Yi Shen, Qing Zhang, Jianjian Zhang, Yanfang Tang, Jin‐ling Zhang, Jia‐jia Hu, Chen‐yi Wu, Jia‐ying Chen, Xun Meng, Shu‐Hui Liu, Feng Wang   +21 more
wiley   +1 more source

CAR-CD34 (+) hematopoietic stem/progenitor cells produced in vivo protect against thoracic aortic aneurysm and dissection

Nature Communications
Thoracic aortic aneurysm and dissection is one of the most devastating cardiovascular diseases, with limited medical intervention options. This study aims to develop chimeric antigen receptor-engineered CD34+ hematopoietic stem/progenitor cells and ...
Kaiwen Zhao, Yuzhen He, Renqi Yao, Shuangshuang Li, Lingxu Kong, Jinzhu Niu, Zan Zeng, Pengcheng Du, Hongqiao Zhu, Rong Zhao, Taiping Liang, Zaiping Jing, Jian Zhou   +12 more
doaj   +1 more source

A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer

, 2016
A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to ...
Miles H Prince (13534000), Phillip K Darcy (13533889), Liza B John (13533970), Joseph A Trapani (13534003), Michael H Kershaw (13533892), Ricky W Johnstone (9191006), Christel Devaud (290074), Carmen SM Yong (15789296)   +7 more
core  

FOXP1 Knockdown Reprograms Th9 CAR‐T Cells to Overcome Antigen Escape

Advanced Science, EarlyView.
FOXP1 knockdown enhances Th9 CAR‐T cell function by promoting IL‐9 production, effector activation, and reduced exhaustion. Reprogrammed Th9 CAR‐T cells strengthen direct tumor killing and activate endogenous antitumor immunity through dendritic cells and CD8+ T cells, thereby suppressing both antigen‐positive and antigen‐loss tumor growth and ...
Yihan Zhu, Xingwei Xie, Xiaohuan Wu, Suidong Ouyang, Yang Zhou, Kang Wen, Yutong Zhong, Yuyang Chen, Handuo Wang, Yuan Gao, Ling Jiang, Hui Li, Wenli Zhao, Abai Xu, Enguang Bi   +14 more
wiley   +1 more source

Engineered T Cell Therapies from a Drug Development Viewpoint

Engineering, 2019
Cancer is one of the leading causes of death worldwide. Recent advances in cellular therapy have demonstrated that this platform has the potential to give patients with certain cancers a second chance at life.
Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey   +5 more
doaj   +1 more source

Efficacy and safety of Chimeric Antigen Receptor T-Cell (CAR-T) therapy in hematologic malignancies: A living systematic review

, 2023
This living systematic review aims to provide a timely, rigorous and continuously updated summary of the evidence available on the role of Chimeric Antigen Receptor T-Cell (CAR-T) therapy for the treatment of patients with hematologic ...
Juan Erviti, Angie Santafe Garcia, Camila Ávila, Francisca Verdugo, María Ximena Rojas Reyes, Luis Carlos Saiz Fernández, Marta Gutiérrez Valencia, Laura Lizeth Trujillo Vargas, Leire Leache, Gerard Urrutia, Ariadna Auladell Rispau   +10 more
core   +1 more source